The Innovative Partnership for Action Against Cancer (iPAAC) is funded by the European Union’s Third Health Programme and aims to develop innovative approaches tackling unaddressed issues in cancer control. Targeting both EU-level policymakers and decision makers at national, regional and local level, the iPAAC focuses on implementation of the outcomes of the European Partnership for Action Against Cancer (EPAAC) and Cancer Control (CANCON) Joint Actions. This Joint Action will run from April 2018 until April 2021.
The iPAAC will support Member States by delivering a Roadmap on Implementation and Sustainability of Cancer Control Actions as its central comprehensive deliverable. This roadmap focuses on issues relevant to policymakers as represented by CANCON and iPAAC recommendations.
Another objective is the development of cancer prevention through a review of current and assessment of potential cancer screening programmes, evaluation and assessment of the possible effect of genomics on cancer control, and the assessment of the implementation European Code Against Cancer.
Additionally, the iPAAC aims to provide better efficacy for dealing with neglected cancers, support the introduction of immunotherapies into clinical practice, evaluate cancer care in European countries and improve the responsiveness to the needs of cancer patients.
The European Cancer Patient Coalition (ECPC) will contribute to 3 Work Packages (WPs). For WP2 ‘Dissemination’, ECPC will prepare and organise 2 conference meetings to address representatives for all relevant cancer patient organisations and actively support networking and mapping of contacts with patient organisations.
For WP7 ‘Cancer Information and Registries’, ECPC will contribute to guidelines, which will be delivered after piloting a comprehensive ICT model. Additionally, ECPC will advise on the selection of epidemiological indicators on cancer prevalence and survivorship and disseminate the result.
Lastly, in WP8 ‘Challenges in Cancer Care’ ECPC will participate in a consensus meeting to define the definition of neglected cancers using the case for pancreatic cancer and cooperate to carry out an expert workshop.
ECPC: Isabelle Manneh-Vangramberen, ECPC Head of Health and Research Programmes
The Joint Action is funded by the